Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients

Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab

“…Patients with multifocal lesions showed higher rates of cutaneous relapse and shorter disease-free survival. Overall survival was favorable (93% at 5 and 10 years) 7 . In another series, CNS involvement was reported in 2% of all primary cutaneous B-cell lymphomas.…”

Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T‐cell and B‐cell lymphoproliferative disorders

“…There were 20 relevant papers for B‐cell LPD (Table ) . Six papers examined cutaneous B‐cell lymphoma (CBCL) in general, 4 were specific for marginal zone lymphoma (MZL), 1 specific for follicle center lymphoma (FCL), 1 specific for intravascular large B‐cell lymphoma and 8 specific for cutaneous lymphoid hyperplasia (CLH), B‐cell type . No papers examined clonality assays in plasmablastic lymphomas or concentrated on clonality testing of large B‐cell lymphoma, leg type (LBCL‐LT), although some papers examining CBCL included cases of LBCL‐LT.…”

“…MZL was often tested, both to characterize the clonality status of true lymphomas (10 papers) [8][9][10][11][12][16][17][18][19][20] and to assess MZL-like CLH (10 papers). [2][3][4][5][6][7]11,15,16,18 Fewer papers examined true FCL (7 papers) 8,10,11,13,16,17,21 and FCL-like CLH (6 papers).…”

Outcomes of radiation therapy of indolent cutaneous B‐cell lymphomas and literature review

“…Marginal zone B cells characteristically express bcl‐2, but lack bcl‐6 or CD10 expression . The place of radiotherapy is well established for the treatment of these two entities with a complete response (CR) in approximately 90% of cases and a disease‐free survival (DFS) of 47 months (IQR: 26–66) and 5‐year DFS of 45% and 70% for PCMZL and PCFCL, respectively. Surgery followed by a ‘wait and watch’ policy is more frequent for PCMZL than for PCFCL.…”

“…Recurrences may occur outside the irradiated areas. In case of multifocal lesions, treatment may include observation, radiotherapy, topical intralesional steroids or rituximab or chemotherapy . In most of the studies, only acute adverse events were reported .…”